MAJOR SHAREHOLDERS 18 The table below sets forth our fully-diluted share capital structure, based on available information as of the date of this Registration Document. Shareholders Number of shares/ % of share capital/ voting rights voting right (fully diluted) 5% Shareholders: Novartis Pharma AG 3,521,774 13 .03% Versant 3,280,381 12.13% Abingworth Bioventures VI LP 3,139,973 (1) 11.61% Fidelity Management & Research Company 1,628,865 (2) 6.02% Bpifrance Participations 2,000,000 7.40% Vitavest S.à.r.l 1,339,706 4.96% Bpifrance Investissement 975,666 3.61% Directors and Executive Officers: Bernard Gilly 1,108,600 4.10% Thomas Gidoin 400,000 1.48% Barrett Katz 300,000 1.11% Didier Pruneau(3) 187,333 0.69% Peter Goodfellow 57,000 0.21% Michael Wyzga 86,000 0.32% Simone Seiter 30,000 0.11% Guido Magni — — Natalie Mount 30,000 0.11% Charlotte Corbaz — — Employee Shareholding 947,000 3.50% Other Shareholders (total) 7,993,601 29.60% TOTAL 27,035,899 100% (1) This amount does not include 1.60 partial shares resulting from the share split on September 3, 2015. (2) This amount does not include 6.80 partial shares resulting from the share split on September 3, 2015, as per public filing dated January 31, 2018. (3) Didier Pruneau retired on February 27, 2018. To our knowledge, at the time of this Registration Document, Bpifrance Participations and Bpifrance Investissement are not acting in concert. GENSIGHT BIOLOGICS – 2017 Registration Document– 177